(4) The clinical study by Fujioka M. et al. targeting DFNB4 deafness was excluded because it targets a syndromic form of SNHL and also does not deal with a gene therapy approach [19]. This evidence concerns the gene SLC26A4 and sensorineural hearing loss disorder.